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It is important to have accurate knowledge of the range of cancers associated with various CHEK2 mutations, and of the lifetime risks
of cancer associated with each. We wished to establish the relationship between family history, mutation type and cancer risk in
families with a CHEK2 mutation. We obtained a blood sample and pedigree information from 2012 unselected women with breast
cancer, from 2007 men with prostate cancer and from 1934 patients with colon cancer, from hospitals throughout Poland. Genetic
testing was carried out for four founder CHEK2 mutations on all 5953 specimens and 533 carriers were identified. We estimated the
risk to age 75 for any cancer in the 2544 first-degree relatives to be 22.3%. After adjusting for mutation type, the risk of breast cancer
was much higher among relatives of probands with breast cancer than among relatives of patients with prostate or colon cancer
(HR¼3.6; 95% CI¼2.1–6.2; P¼0.0001). Similarly, the risk of prostate cancer was higher among relatives of probands with prostate
cancer than among relatives of patients with breast or colon cancer (HR¼4.4; 95% CI¼2.2–8.7; P¼0.0001) and the risk of colon
cancer was higher among relatives of probands with colon cancer than among relatives of patients with prostate or breast cancer
(HR¼4.2; 95% CI¼2.4–7.8; P¼0.0001). These analyses suggest that the risk of cancer in a carrier of a CHEK2 mutation is
dependent on the family history of cancer.
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In Poland, there are four founder mutations in CHEK2, including
three truncating mutations (1100delC, IVS2þ1G4A, del5395) and
one missense mutation (I157T; Cybulski et al, 2004a, 2007a).
CHEK2 mutations predispose men and women to a range of cancer
types, including breast, prostate and colon (Cybulski et al, 2004b;
Cybulski et al, 2007b). For breast and prostate cancer, the
truncating mutations are associated with higher penetrance than
the missense mutation (Cybulski et al, 2007c). For colon cancer,
only the missense variant I157T is associated with an elevated risk
(Cybulski et al, 2007b). The odds ratios reported to be associated
with truncating and missense mutations for breast, prostate and
colon cancer in our most recent studies are presented in Table 1.
Screening for CHEK2 mutations has not been well integrated
into genetic counselling for cancer (Narod and Lynch, 2007).
To some extent, this reflects the rarity of CHEK2 mutations
and the differences in the prevalence of mutations from country
to country. Only one mutation, 1100delC, appears to be widely
disseminated (CHEK2 Breast Cancer Case-Control Consortium,
2004; Weischer et al, 2008; Zhang et al, 2008). Uncertainty remains
as to the best estimate of cancer risk for gene carriers, and the
factors which influence the penetrance of the CHEK2 gene.
Different methods have been used to measure penetrance; but it
is generally accepted that studies based on series of unselected
patients are superior to those based on cases selected for family
history (Begg, 2002; Risch and Narod, 2003). If there are risk
factors, which cluster within families, and which predispose to a
cancer at a particular site, then we expect the risk of cancer in close
relatives to depend on whether the proband was affected with the
same type of cancer or with a different type.
We conducted population surveys on unselected cases of breast
cancer, prostate cancer and colon cancer. Poland is well suited
for association studies because the population is genetically
homogenous and because of high patient participation rates. The
patients underwent genetic testing for the four founder CHEK2
mutations. Patients with mutations were questioned regarding
details about all cancers in their first-degree relatives. Using this
data, we are able to estimate the cumulative incidence of all
cancers in the first-degree relatives of the carriers, and to compare
the risks by specific CHEK2 mutation, and by the disease status of
the index case (breast or prostate or colon cancer).
MATERIALS AND METHODS
Study subjects
In the course of a national breast cancer survey, we interviewed
2012 women diagnosed with breast cancer at one of the seven
centres situated throughout Poland from 2002 to 2003.
Received 5 January 2009; revised 11 March 2009; accepted 20 March
2009
*Correspondence: Dr SA Narod; E-mail: steven.narod@wchospital.ca
British Journal of Cancer (2009) 100, 1508–1512
& 2009 Cancer Research UK All rights reserved 0007– 0920/09 $32.00
www.bjcancer.com
E
p
i
d
e
m
i
o
l
o
g
yA total of 1934 patients with colon cancer were interviewed from
1998 to 2007 at 11 centres situated throughout Poland. The first
1050 colon cancer patients have been described in detail previously
(Cybulski et al, 2007b). The study has since been extended to
include more patients using the same methodology. In all, 2007
patients with prostate cancer were interviewed from 1999 to 2007
at 13 centres situated throughout Poland. The cancer patients have
been described in detail previously (Cybulski et al, 2004b; Cybulski
et al, 2007c). The study was approved by the ethics board of the
Pomeranian Medical University.
Laboratory analyses
A DNA sample was obtained from peripheral blood from each
patient. These samples were assayed for four founder mutations
in CHEK2 gene (1100delC, IVS2þ1G4A, del5395 and I157T).
Methods have been described elsewhere (Cybulski et al, 2004a,
2007a).
Pedigree data
The patient (index case with mutation) was interviewed in person
or on the telephone by a member of the research team. He or she
was asked to provide complete information about cancers in all
first-degree relatives, including type of cancer, age of onset, age of
death and current age of relatives without cancer. For unaffected
relatives, age of death was recorded (if deceased) or current age (if
alive). The diagnoses of cancer in the relatives were not confirmed
by reference to pathology reports. Patients were unaware of their
mutation status at the time of interview. Because of ambiguity
expressed by probands in distinguishing ovarian, cervical and
uterine cancer in relatives, these three sites were merged (female
genital tract).
Statistical analysis
We estimated the cancer risk for first-degree relatives of mutation
carriers for all mutations and for each mutation separately,
using Kaplan–Meier survival analysis. Subjects were considered to
be at risk of cancer from birth until either the development of
cancer; death from another cause; the date of patient interview or
until the age of 75 years. Cumulative incidence curves were
computed separately for each site of cancer and for all cancers
combined (any cancer). Risks were computed separately for
truncating versus missense CHEK2 mutations. Risks were com-
puted for men and for women and for both sexes combined.
Risks were compared for relatives of patients with cancer at the
same site, and for cancers at different sites. To establish which
of these factors were relevant for predicting the lifetime risk of
cancer of each type, a Cox proportional hazards model was used
which incorporated both the mutation type (missense versus
truncating) and the site of disease in the proband (breast or colon
or prostate).
RESULTS
Among the 5953 unselected Polish individuals with cancer in this
study, 533 CHEK2 mutation carriers were identified, including 186
probands with breast cancer (9.2% of the total tested) (mean age of
diagnosis: 55.6 years; range: 27–82 years), 147 probands with
colon cancer (7.6% of total; mean age of diagnosis: 61.9 years;
range: 25–88 years) and 200 probands with prostate cancer (10.0%
of total; mean age of diagnosis: 65.7 years; range: 45–88 years).
A total of 515 (96.6%) pedigrees contained sufficient data for
statistical analysis. In total, these 515 pedigrees recorded 2544 first-
degree relatives (1270 men and 1274 women). In all, 431 cancers
were reported in the 2544 relatives (213 in men and 218 in women;
Table 2). Data were missing for four subjects and these were
excluded, leaving 2540 first-degree relatives for analysis.
A total of 15.5% of the female relatives and 14.3% of the male
relatives have been diagnosed with some type of cancer by the age
of 75. The cumulative risks of cancer at any of these sites among
the first-degree relatives of the CHEK2 mutation carriers are
shown in Table 3. For example, the risk of breast cancer to age 50
for first-degree relatives of breast cancer patients with the
missense mutation was 3.2%, compared to a risk of 1.4% for
women who were first-degree relatives of all individuals with this
mutation. The risk of breast cancer for all female first-degree
relatives of all truncating mutation carriers was estimated to be
7.6% to age 75, and of relatives of the missense mutations was
5.3%. The risk of prostate cancer for all first-degree relatives of all
truncating mutation carriers was estimated to be 6.1% to age 75,
and of missense mutations was 7.2%. The risk of colon cancer
for all first-degree relatives of all truncating mutation carriers
was estimated to be 2.0% to age 75, and of missense mutations
was 3.5%.
The lifetime risk of cancer was higher for a specific cancer type
when that type of cancer was also diagnosed in the proband
(compared to a different site in the proband). The risk to age 75 for
breast cancer among relatives of women with breast cancer was
10.4% compared to a 3.6% lifetime breast cancer risk among
relatives of patients with colon or prostate cancer (Figure 1). The
risk to age 75 for colon cancer among relatives of individuals with
colon cancer was 7.0%, compared to a 1.9% lifetime colon cancer
risk among relatives of patients with breast or prostate cancer
(Figure 2). The risk to age 75 for prostate cancer among relatives of
men with prostate cancer was 12.1%, compared to a 3.0% lifetime
prostate cancer risk among relatives of patients with colon or
breast cancer (Figure 3).
We constructed a Cox proportional hazard model to express the
cancer risks for first-degree relatives of patients with mutations. A
separate model was constructed for predicting the risks of breast,
colon and prostate cancer in the first-degree relatives. For each
model, the data were analysed with respect to the type of cancer
Table 2 Distribution of 431 cancers observed in first-degree relatives
Cancer site Number
Prostate 68
Female genital 64
Breast 59
Colon 53
Stomach 38
Lung 33
Leukaemia 15
Liver 14
Pancreas 12
Kidney 10
Other 59
Total 431
Female genital includes ovary, uterine and cervical.
Table 1 Odds ratios associated with truncating and missense CHEK2
mutations
Site of
cancer
Truncating
mutation
OR (95%CI)
Missense
mutations
OR (95% CI) Reference
Prostate 2.5 (1.6–3.7) 1.6 (1.3–2.1) Cybulski et al (2004b)
Breast 3.3 (2.4–4.3) 1.6 (1.4–1.9) Cybulski et al (2007a)
Colon 1.0 (0.5–1.8) 1.5 (1.2–2.0) Cybulski et al (2007b)
CI¼confidence interval; OR¼odds ratio.
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class of mutation (truncating versus missense). The relatives of
breast cancer patients experienced a greater risk of breast cancer
than did the relatives of the patients with other cancers (Table 4).
A survival analysis using Cox regression estimated that the
relatives of prostate/colon cancer patients experienced only
approximately one-fourth the risk of breast cancer as did the
relatives of breast cancer patients (Table 4). Similar results were
obtained for prostate and colon cancer (Tables 5 and 6).
DISCUSSION
CHEK2 mutations confer substantial risks for breast, prostate and
colon cancer, but the cancer risk appears to vary between and
Table 3 Estimated cumulative risks for breast, prostate, colon and all cancers for first-degree relatives of patients with founder CHEK2 mutations
Cancer site
in relatives
CHEK2
mutation type
Cancer risk to age 50;
same site in proband
Cancer risk to age of 50;
all sites in proband
Cancer risk to age 75;
same site in proband
Cancer risk to age of 75;
all sites in proband
Breast Missense 0.032 0.014 0.108 0.053
Truncating 0.069 0.035 0.091 0.076
Either 0.042 0.019 0.104 0.059
Colon Missense 0.015 0.005 0.075 0.035
Truncating 0.000 0.000 0.046 0.020
Either 0.012 0.003 0.070 0.031
Prostate Missense 0.013 0.002 0.120 0.072
Truncating 0.000 0.000 0.119 0.061
Either 0.002 0.002 0.121 0.070
Any Missense — 0.039 — 0.216
Truncating — 0.045 — 0.248
Either — 0.041 — 0.223
0.16
0.14
Breast (34 cases of 427)
Colon/prostate (22 cases of 846)
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Figure 1 Cumulative incidence of breast cancer among first-degree
female relatives of CHEK2 mutation carriers, by site of cancer in proband.
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Figure 2 Cumulative incidence of prostate cancer among first-degree
male relatives of CHEK2 mutation carriers, by site of cancer in proband.
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Figure 3 Cumulative incidence of colon cancer among first-degree
relatives of CHEK2 mutation carriers, by site of cancer in proband.
Table 4 Risk factors for cancer in first-degree relatives of CHEK2 carriers
and effects of mutations
HR 95% CI P-value
Breast cancer
Breast cancer in proband versus other 3.6 2.1–6.2 0.000004
Truncating versus missense mutation 1.4 0.8–2.5 0.2
Prostate cancer
Prostate cancer in proband versus other 4.4 2.2–8.7 0.00002
Truncating versus missense mutation 0.98 0.5–2.0 0.9
Colon cancer
Colon cancer in proband versus other 4.2 2.4–7.8 0.000002
Truncating versus missense mutation 0.6 0.3–1.4 0.2
CI¼confidence interval; HR¼hazard ratio.
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risks associated with different mutations, modifying genetic
background and environmental or lifestyle factors. Ours is
the first study to show that, among relatives of CHEK2 mutation
carriers, the risks of breast, prostate and colon cancer differ
dramatically depending on the type of cancer diagnosed in
the proband. This supports the importance of the contribution
of genetic background to risk modification in hereditary
cancer syndromes (Byrnes et al, 2008). Environmental and
lifestyle factors also play important roles, but these were not the
topic of the current study. Our observation of a high degree
of concordance in the clinical expression of cancer within a
family is most readily explained by the existence of one or more
modifying genes. Our data imply that the genetic modifiers are
different for the three sites. For a given site, the underlying model
might involve two genes, or represent a polygenic effect. In the
simplest manifestation of a two-gene model, it would be necessary
for a carrier of a deleterious CHEK2 mutation also to carry a
specific allele of a second gene to develop cancer. If so, then all
affected carriers would carry both alleles. The probability of a
sibling inheriting both alleles would be 25%. Three of four siblings
would not be at elevated risk for the index cancer and we would
observe poor segregation in families between cancer and the
presence of CHEK2 mutation.
The risks of breast cancer in first-degree relatives differed
significantly, depending on whether the proband was diagnosed
with breast cancer or another type of cancer. Our data support the
model proposed by Byrnes et al (2008), whereby the risks
associated with the cancer family history and with the genetic
mutation act in combination (and are possibly multiplicative).
We have reported a similar finding among BRCA1 mutation
carriers identified through unselected cases of breast or ovarian
cancer (Warner et al, 1999; Moslehi et al, 2000; Gronwald et al,
2006) that is, among BRCA1 carriers, the risk of breast cancer was
dependent on whether the affected relative had breast or ovarian
cancer. The risk of ovarian cancer, however, was similar in the
two groups of relatives (Warner et al, 1999; Moslehi et al, 2000;
Gronwald et al, 2006). This suggests that among BRCA1 carriers,
there are familial genetic modifiers for breast, but not for ovarian
cancer. However, the familial modifying effects for CHEK2 on
the risks of breast, colon and prostate cancer observed here
were more extreme than those seen in our earlier studies of
BRCA1 carriers.
Both truncating and missense CHEK2 mutations predispose to
prostate cancer (Cybulski et al, 2007c). One modifying gene has
been proposed for prostate cancer; using this database, we have
recently shown that the risk of prostate cancer depends on the
genotype of p27 (Cybulski et al, 2007c). The excess risk of prostate
cancer attributable to a CHEK2 mutation was restricted to carriers
of the VV genotype at p27. A similar effect was seen with the p27
genotype and the risk of colon cancer (Cybulski et al, 2007c).
However, the p27 genotype did not modify the risk of breast cancer
among CHEK2 carriers. We have recently shown that, among
carriers of CHEK2 mutations, the risk of breast cancer was much
greater for women who also carried a specific missense variant in
BRCA2 and the interaction was statistically significant (P¼0.03;
Serrano-Ferna ´ndez et al, 2008). BRCA2 is the first CHEK2-
modifying gene proposed for breast cancer; however, the relevant
BRCA2 allele (T1915M) was rare and was present in only 6% of the
population controls and in 11% of the cases of CHEK2-associated
breast cancer. It is likely that there are other risk-modifying genes
and innovative strategies will be required to find these.
There are several strengths of our study. Ours is the only
large single-centre study of unselected cancer patients originating
in a well-defined, ethnically homogeneous group from one country
to address the genetic epidemiology of CHEK2. Few patients
declined to participate when approached. Subjects were unaware
of their genetic status at the time the family history was
obtained and all patient groups were studied using the same
methods. Nevertheless, some of our individual risk estimates are
imprecise and it will be important to continue to accrue patients
to this and similar studies and to re-examine these questions in
the future.
There are several limitations to our study as well. Despite
the fact that we included a total of 5953 cancer patients, there
were only 533 CHEK2-positive cases and 431 affected relatives.
Many of our subgroup comparisons were based on small
numbers; in particular, we had limited power to compare the
risks associated with the different mutations for the three different
sites. Our end point was the presence of cancer in first-degree
relatives, and we did not have genotype status on the relatives.
Ideally, we would compare cancer risks in relatives with and
without CHEK2 mutations, but the requirement of collecting a
blood or tissue sample from all first-degree relatives, living and
dead, was prohibitive. Cancer diagnoses in relatives were based
on proband recollection and were not confirmed with medical
records. The lifetime risks of the specific cancer types appear
to be low, and to some extent, this might represent incomplete
reporting on the part of the proband; but the incidence rates
for these three cancers are much lower in Poland than in the
United States, and screening for these three sites is not wides-
pread in the country. We did not have information on environ-
mental, medical or lifestyle factors in the relatives. Finally, we did
not have a control group of relatives of unselected, unaffected
probands to measure cancer risk; we were concerned that healthy
controls with a family history of cancer might be more willing
than others to participate in a genetic epidemiology study of
cancer and that if we included self-selected controls, we might
generate biased risks.
The finding of phenotypic heterogeneity among CHEK2 carriers
with the same mutation has potentially important clinical
implications. Genetic counsellors should not provide risks simply
based on the mutation status alone, and must incorporate the
family history into the assessment as well. It is not clear to what
extent the risks for breast, colon or prostate cancer are elevated in
the cohorts of relatives with no family history of cancer at that site.
It is also true that if a woman is found to be a CHEK2 carrier and
has a family history of breast cancer, she is likely to be at high risk
of breast cancer (Byrnes et al, 2008). Given that 70–80% of
CHEK2-associated breast cancers are ER-negative, women with
a mutation may be a good candidates for tamoxifen chemo-
prevention (Cybulski et al, 2009). Similarly, CHEK2 carriers with a
family history of colon or prostate cancer may be good candidates
for intensified surveillance.
Table 5 Risk factors for prostate cancer in first-degree relatives of
CHEK2 carriers
Factor HR 95% CI P-value
Prostate cancer in proband versus other 4.4 2.2–8.7 0.00002
Truncating versus missense mutation 0.98 0.5–2.0 0.9
CI¼confidence interval; HR¼hazard ratio.
Table 6 Risk factors for colon cancer in first-degree relatives of CHEK2
carriers
Factor HR 95% CI P-value
Colon cancer in proband versus other 4.2 2.4–7.8 0.000002
Truncating versus missense mutation 0.6 0.3–1.4 0.2
CI¼confidence interval; HR¼hazard ratio.
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